The update follows a European review of clinical evidence, post-authorisation reports and published literature, which concluded that semaglutide use in adults with type 2 diabetes may be associated with an approximately two-fold increase in the relative risk of developing NAION
Secondary endpoints Secondary endpoints include change in neural response to visual food cues in reward processing regions as assessed by functional MRI, change in body weight, change in fat mass as determined by DXA scan and change in eating behaviour
Poison induced pica in rats
Safety, Side Effects, and Monitoring Review safety considerations before starting or switching semaglutide because GLP-1 medicines affect digestion, glucose levels, and several risk areas
Nausea Diarrhea Vomiting Constipation Stomach pain Indigestion Injection site reactions Feeling tired Allergic reactions Belching Hair loss Gastroesophageal reflux disease (heartburn) You are encouraged to report negative side effects of prescription products to the FDA
But they are not the same medication
